New York State Teachers Retirement System Acquires 14,200 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Teachers Retirement System grew its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 183.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,949 shares of the company's stock after acquiring an additional 14,200 shares during the period. New York State Teachers Retirement System owned 0.06% of TransMedics Group worth $1,477,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Lisanti Capital Growth LLC purchased a new stake in shares of TransMedics Group in the first quarter worth $1,942,000. Perigon Wealth Management LLC raised its position in shares of TransMedics Group by 31.8% in the first quarter. Perigon Wealth Management LLC now owns 18,820 shares of the company's stock worth $1,266,000 after buying an additional 4,543 shares in the last quarter. Global Assets Advisory LLC purchased a new stake in shares of TransMedics Group in the first quarter worth $1,049,000. Sava Infond d.o.o. raised its position in shares of TransMedics Group by 46.7% in the first quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock worth $148,000 after buying an additional 700 shares in the last quarter. Finally, Valmark Advisers Inc. raised its position in shares of TransMedics Group by 4.5% in the first quarter. Valmark Advisers Inc. now owns 7,213 shares of the company's stock worth $485,000 after buying an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Activity

In other news, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the transaction, the director directly owned 732 shares of the company's stock, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TMDX. Oppenheimer increased their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group has an average rating of "Moderate Buy" and a consensus price target of $127.33.

TransMedics Group Price Performance

TMDX traded down $12.32 during trading on Friday, reaching $112.46. The stock had a trading volume of 2,553,123 shares, compared to its average volume of 1,378,790. The stock has a market cap of $3.80 billion, a PE ratio of 82.69 and a beta of 2.06. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The business has a 50-day moving average of $125.49 and a 200-day moving average of $90.65.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The firm's revenue was up 48.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.35 earnings per share. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.